PF
JCR Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| JR-141 (pabinafusp alfa) | Hunter Syndrome (MPS II) | Approved |
| JR-171 (lepunafusp alfa) | Fabry Disease | Phase 3 |
| JR-441 | Sanfilippo Syndrome Type A (MPS IIIA) | Phase 1/2 |
| JR-161 | Gaucher Disease Type 1 | Phase 1 |
| JNT-517 | Phenylketonuria (PKU) | Phase 1 |
| JR-403 | Amyotrophic Lateral Sclerosis (ALS) | Preclinical |
Leadership Team at JCR Pharmaceuticals
KS
Keiyu Sonoda
Representative Director, President & CEO, Chief Scientific Officer
TA
Toru Ashida
Representative Director and Chairman
SA
Shin Ashida
Director and Founder
AS
Andrea Spezzi
Director, Senior Executive Officer
YH
Yoshio Hiyama
Director, Senior Managing Executive Officer, Head of Reliability Assurance
AB
Anne Bechet
Senior Executive Officer, Head of Development, GM JCR Europe, CEO JCR USA
KM
Kazutoshi Mihara
Executive Officer, Head of Research, Director of CMC Development Research Institute
MD
Marc Dunoyer
Outside Director